Physician Sentiment on TAGRISSO®

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update!

Stephen V Liu, MD

@StephenVLiu

It will take a lot of balancing of pros/cons, subset considerations and of course shared decision making to settle on optimal choice Just OS cross-look might end up misleading w good crossover to chemo in FLAURA2 while practically none for ami But a precision onc combo that

Balazs Halmos

@BalazsHalmosMD

Love how the response is that "data suggest that the greatest overall survival benefit is achieved with the use of adjuvant osimertinib, as supported by the results of the ADAURA and FLAURA trials" ...as if there were a trial of salvage vs. adjuvant osimertinib?? The prevailing…

Jeff Ryckman

@jryckman3

Full physician voice list (25)

Physician	Comment (verbatim)	Sentiment	Impressions
Stephen V Liu, MD @StephenVLiu	FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important posi…	Positive	10,394
Jennifer A. Marks, MD @jennifermarksmd	So important to remember - continuation of pemetrexed maintenance on the #FLAURA2 likely is required to derive benefit! @JuliaRotow @asco #ASCO25 @EGFRResisters @DFEGFRcenter #LCSM	Neutral	3,550
Jeff Ryckman @jryckman3	Love how the response is that "data suggest that the greatest overall survival benefit is achieved with the use of adjuvant osimertinib, as supported by the results of the ADAURA and FLAURA trials" ...as if there were a trial of salvage vs.…	Negative	2,504
Eric K. Singhi, MD @lungoncdoc	Always love hearing @JuliaRotow speak! Great to spend time with her in NOLA! BOOKMARK her updated slide! 🔖	Positive	2,417
Oriol Mirallas MD @DrMirallas	#ASCO24 Masterclass by @JordiRemon mechanisms of resistance to #EGFR #NSCLC 1. On-target 🎯 2. Bypass 👣 3. Histo transf #SCLC #SCC 4. Unknown 📌 SoC 1L #FLAURA #MARIPOSA #FLAURA2 📌 CT+/-BEV+/-IO? after #TKI PD no clear #OS ⬆️ HARMONi-A? 👉🏼 Se…	Neutral	2,192
Vinay Prasad MD MPH @VPrasadMDMPH	Osi alone is still fine too Flaura 2 post progression care is not up to the US standard so one doesn't have to add chemo	Negative	1,541
Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD	After FLAURA and ADAURA, we would have expected LAURA to be positive for both PFS and OS. This press release is very encouraging!	Positive	677
Balazs Halmos @BalazsHalmosMD	It will take a lot of balancing of pros/cons, subset considerations and of course shared decision making to settle on optimal choice Just OS cross-look might end up misleading w good crossover to chemo in FLAURA2 while practically none for…	Nuanced	624
Bertrand Delsuc @BertrandBio	It's my understanding that Astra positions FLAURA2 only for subpopulations like pts with brain mets or other subgroups of interest with a larger clinical benefit than in ITT, given the tox addon of chemo. For the other settings, they're cur…	Neutral	113
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD	💥 #ESMO19 #LCSM #lungcancer FLAURA trial showed a statistically significant improvement in OS (38.6 vs 31.8m = 6.8 m) for pts treated w/ Osi (HR 0.79). These results confirm t role of OSI as the corner stone for common EGFR+ NSCLC. @EGFRR…	Neutral	0
Dr Riyaz Shah @DrRiyazShah	FLAURA final OS; mOS 38.6m. That’s enough for me. Slam dunk. Khallas. Time to move on. #LCSM #ESMO19	Neutral	0
H. Jack West, MD, FASCO @JackWestMD	Not exactly non-Asians doing better than Asians. Asians did just as well with first gen EGFR TKIs as with osimertinib. Non-Asians did better w/osimertinib. Could be diff in biology, diffs in health care systems where pts were treated, or so…	Neutral	0
Joshua Bauml, MD @Jbauml	Given early separation of curves between osimertinib and gefitinib/erlotinib in FLAURA, I wonder if osimertinib could overcome the need for concurrent chemotherapy. Interesting study, but will need to be validated with osimertinib before I…	Nuanced	0
Dr. Estela Rodriguez @Latinamd	If you were still debating if osimertinib was better than gefitinib/Erlotinib: FLAURA OS update presented by @RamalingamMD at #ESMO19: MS OS 38.6 vs 31.8 mos, impressive 54% ⬇️ in CNS progression (HR 0.48), we still need better drugs for ra…	Positive	0
Lecia Sequist, MD, MPH, FASCO @LeciaSequist	FLAURA study design #esmo17. Power based on mPFS 10 to 14 mo	Neutral	0
Marco Tagliamento @M_Tagliamento	2nd line treatment following PD in the two arms of #FLAURA trial. New data to discuss about the best first vs sequence. #ESMO19 #LCSM #OncoAlert	Neutral	0
Sandip Patel MD FASCO @PatelOncology	Completely agree, any data on brain mets here?	Neutral	0
Patrick C. Ma, MD @PatrickCMa1	Quite intriguing data. Wonder if it has to do with CNS mets difference btw the two groups: Asian vs Non-Asian... 🤔	Neutral	0
Santhosh Ambika @RenoHemonc	Question becomes Osi + chemo will be better in pts with p53 mutations upfront	Neutral	0
Dr. Antonio Calles 🫁🚭 @Tony_Calles	Final OS analysis from FLAURA trial. 🤫 Don’t tell @EMA_News Exon21 L858R EGFR mutation doesn’t show overall survival benefit from osimertinib. #ESMO19 #LCSM	Neutral	0
Carlos Alvarez @duemed	#ESMO19 On FLAURA: - positive trial (PFS) with important OS results - this is a secondary endpoint; i have some concerns about the protocol and what is now presented (power and death events). From 380 to 318 death events. Statistics adjuste…	Positive	0
DENIS @marcdenisnantes	And there you go ! #ESMO19 #FLAURA #osimertinib @AstraZeneca	Neutral	0
Nathan A. Pennell MD, PhD, FASCO @n8pennell	7 month improvement in median OS with osimertinib compared to first gen TKI in FLAURA ⁦@RamalingamMD⁩ #ESMO19 #LCSM	Neutral	0
Nirmal Raut @oncologician	The “T790M paradox” - prognosis is better if T790M is acquired rather than present at baseline .Does this explain the confidence intervals straddling the line of unity in the L858R subgroup ? #ESMO19 #FLAURAOS @RamalingamMD	Neutral	0
Matthias Scheffler @trnsltnl	Still not sure what to think of the #FLAURA results presented at #ESMO19 for EGFRmut #lungcancer. So up to you: do the results justify the use of osimertinib as SoC 1st line, or have they even strengthen sequences? @EGFRResisters @EgfrUk ?	Neutral	0

See full FLAURA conference coverage & trial data →

Trial 2 · NCT04035486

What do oncologists think of the FLAURA2 trial (TAGRISSO®)?

FLAURA2 — First-line metastatic EGFR-mutated NSCLC — osimertinib + platinum-pemetrexed chemotherapy

FDA APPROVED · Feb 2024FDA-approved February 16, 2024, in combination with platinum-based chemotherapy for the first-line treatment of metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

Physicians are broadly favorable, with real nuance on FLAURA2: 21% of 66 verified physician voices positive, 18% nuanced (praising the result while flagging a caveat), 53% neutral, 8% critical.

21%

18%

53%

Positive 21% Nuanced 18% Neutral 53% Critical 8%

Denominator: 66 distinct verified physician voices across 174 oncologist posts, 2023-09-11 to 2026-03-25. Sponsor: AstraZeneca

See full FLAURA2 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04035486 · FDA — FLAURA2 osimertinib + chemotherapy approval (Feb 2024)

FDA approval (February 16, 2024): osimertinib with platinum-based chemotherapy for first-line metastatic EGFR-mutated NSCLC (based on FLAURA2, NCT04035486).

Physician voices — verbatim

FLAURA2 now FDA approved. It’s the biggest change in this space for some years. I’ll be fascinated to see how this gets used. All comers? Brain mets predominantly? Many patients welcome the opportunity to avoid chemo.

Dr Riyaz Shah

@DrRiyazShah

So much awaited data of flaura2 .29 .4 months. Very good PFS for CNS mets also. 24.9 months . But no OS as of now . Is more toxicity justified if NO OS ? @JackWestMD @PatelOncology @FordePatrick @StephenVLiu @DrSteveMartin #WCLC2023

Dr Amol Akhade

@SuyogCancer

FDA has no standards Approving chemo + Osi based on FLAURA2 is a terrible decision Osi -> chemo may have similar or better OS with better QoL. FDA has no clue. They are permitting an option that could worsen outcomes for people. Terrible decision, par for course

Vinay Prasad MD MPH

@VPrasadMDMPH

Full physician voice list (66)

Physician	Comment (verbatim)	Sentiment	Impressions
Vinay Prasad MD MPH @VPrasadMDMPH	FDA has no standards Approving chemo + Osi based on FLAURA2 is a terrible decision Osi -> chemo may have similar or better OS with better QoL. FDA has no clue. They are permitting an option that could worsen outcomes for people. Terrible…	Negative	42,184
Dr Amol Akhade @SuyogCancer	So much awaited data of flaura2 .29 .4 months. Very good PFS for CNS mets also. 24.9 months . But no OS as of now . Is more toxicity justified if NO OS ? @JackWestMD @PatelOncology @FordePatrick @StephenVLiu @DrSteveMartin #WCLC2023	Nuanced	24,807
Dr Riyaz Shah @DrRiyazShah	FLAURA2 now FDA approved. It’s the biggest change in this space for some years. I’ll be fascinated to see how this gets used. All comers? Brain mets predominantly? Many patients welcome the opportunity to avoid chemo.	Positive	22,010
Stephen V Liu, MD @StephenVLiu	Dr. @dplanchard at #WCLC25 with highly anticipated Presidential Plenary presentation with OS results from FLAURA2: first line chemo + osimertinib improves OS from 37.6 to 47.5m, HR 0.77, 4y OS rate 41% to 49%. Benefit seen across subgroups.…	Neutral	19,071
d.planchard @dplanchard	FLAURA2 regimen raises the bar! New data from a China study shows impressive PFS/OS gains for Osi + Chemo in EGFRm + TP53 co-mutated pts. Confirms 1L SOC status across the board: TP53 mut, WT, and Asian subgroups…Finding a better future str…	Positive	18,468
Benjamin Besse @BenjaminBesseMD	EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts would…	Nuanced	14,954
Patrick Forde @FordePatrick	Same phenomenon occurs in #MARIPOSA as noted by Dr. @harpreet_md in #FLAURA2 - its minor but perhaps early increase toxicity with intensified treatment is bad for some patients outcome? #WCLC2025 #lcsm https://t.co/3eIcoNtrHW	Nuanced	13,441
Eric K. Singhi, MD @lungoncdoc	LOVE that this was included in the #FLAURA2 discussion!! We need to hear thoughts directly from patients and their families!!	Positive	13,329
Rami Manochakian MD, FASCO Cancer Education @RManochakian	🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clini…	Positive	12,958
Oncology Brothers @OncBrothers	Updated data on combination options seen at #ESMO25 for metastatic non-small cell lung cancer w/ EGFR mutated disease. Stuck w/ cross trial comparisons for now! We touched on this data and our options 👇👇 with @lungoncdoc! @EGFRSummit #OncT…	Neutral	11,927
H. Jack West, MD, FASCO @JackWestMD	Brain mets, you mean, in last bit? Interesting, because we’ve long considered osi to be most active component for intracranial activity & haven’t attributed much CNS activity to std chemo historically. In the end, key Q for many will be …	Neutral	11,701
Dr. Antonio Calles 🫁🚭 @Tony_Calles	🧠 FLAURA2: CNS activity with osimertinib + chemo vs osimertinib alone. @dplanchard 💊 Now you have a subgroup of patients with EGFR mutation who can benefit from treatment intensification upfront. #ESMO23 #LCSM @EGFRResisters	Neutral	11,413
Katsuaki Maehara 🇯🇵 @KatsuakiMaehara	🫁 FLAURA2 & MARIPOSA 🫁 @ASCOPost 🌟 OS - Interim analysis 🌟 　 ⚠️ INDIRECT ⚠️ 📌 Conditional Power used at the time of the interim analysis as indicated in the #WCLC24 discussion, MARIPOSA's H0 is 48%. https://t.co/R4lfF92Twx	Neutral	10,802
Jordi Remon @JordiRemon	🎉FLAURA2 in EGFR-mut aNSCLC is➕ Escalating 🏔️ ttx in blinded way provides toxicity, not all need intensive ttx. CT-DNA status before EGFR TKI (data from FLAURA) is poor prog marker.These are the patients who may benefit of intense ttx.Only …	Positive	8,706
Jarushka Naidoo @DrJNaidoo	#WCLC25 Presidential Superb FLAURA2 OS discussion by @danieltanmd, main questions: - combo may ⬆️likelihood of long-term response? - clinical/molec/ctDNA factors relevant - refinement needs complex integration of factors Extremely elegan…	Positive	7,626
Balazs Halmos @BalazsHalmosMD	Press release, press release! OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play on OS they have nothing to hide! With OS being the 🐘in the room and both MARIPOSA and FLAURA2 reaching this key endpoin…	Neutral	7,322
Giannis Mountzios @g_mountzios	An excellent debate here in #ELCC25 on the optimal choice for 1st Line treatment of EGFR pos #NSCLC : ⭐️. Osimertinib monotherapy VS Combinations (FLAURA2/MARIPOSA) Insightful lectures by @ZPiotrowskaMD and @APassaroMD focusing on e…	Positive	6,986
Chul Kim @chulkimMD	Impactful discussion by Dr. Tan dissecting the data behind the OS benefit from #FLAURA2. Potential OS benefit from synergistic effect delaying resistance, better CNS control, ensuring receipt of chemo. Many ongoing first-line trials may…	Neutral	6,552
Tejas Patil @TejasPatilMD	Magnitude of OS benefit for FLAURA2 will be relevant here. Since crossover was not mandated per study design, the next question should be what did the control arm receive and when? IMO - the central clinical, real world, question that FLA…	Neutral	5,856
Yakup Ergün @dr_yakupergun	#ESMO25 / @NEJM FLAURA2 final OS Osimertinib + Chemo vs osimertinib alone in 1L EGFR+ NSCLC: ✅️OS 47.5 vs 37.6 mo (HR 0.77) 💬Confirms dual-therapy as new 1L option for fit EGFR-mutant patients. Between MARIPOSA and FLAURA2, my persona…	Neutral	5,739
David Gandara @drgandara	At Cal Cancer Consortium conference, Jonathan Riess shows impact of baseline positive vs negative plasma ctDNA for EGFR in the FLAURA2 trial. Addition of chemo to Osi mainly benefitting those with positive ctDNA. Food for thought! @UCD_Can…	Positive	4,614
Hidehito HORINOUCHI @HHorinouchi	🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️@AstraZeneca @OncoAlert @Larvol #EGFR @EGFRResisters https://t.co…	Positive	4,280
C. Jillian Tsai, MD, PhD @CJTsaiMDPhD	Wonderful results - can't wait to see more details. BUT- when/why do we endorse PFS as the valid primary endpoint in drug trials in the definitive treatment, but insist on OS for some Ph3 RT trials in metastatic cancer? As we often argued…	Nuanced	3,700
Rita Leporati @Ritalepp	FLAURA2 exploratory analysis discussion by @marinagarassino at #AACR24: 🔺dynamic ctDNA analysis not useful for clinical decisions 🔹baseline detection of EGFRm is prognostic and may select for a higher degree of clinical benefit from Osi+CT …	Neutral	3,606
Jennifer A. Marks, MD @jennifermarksmd	So important to remember - continuation of pemetrexed maintenance on the #FLAURA2 likely is required to derive benefit! @JuliaRotow @asco #ASCO25 @EGFRResisters @DFEGFRcenter #LCSM	Neutral	3,550
Christian Rolfo @ChristianRolfo	Dr Wu raising important questions in his excellent discussion on the FLAURA2 trial. Toxicity, OS data will clarify the future of the combination, real benefit in subgroups, resist and mechanisms? Patients and Md point of view?@ThomasW35874…	Neutral	3,469
Bartomeu Massuti @bmassutis	In FLAURA2 trial chemotherapy plus Osimertinib increases survival vs Osi single agent with HR 0.77 and median survival 47.5 months and 45% patients alived at 4 years. Is still a role for Osimertinib single agent? @OncoAlert #WCLC25	Neutral	3,361
Kelsey Pan, MD, MPH @KelseyPanMD	10/20 #TumorBoardTuesday 👨🏽‍🏫Mini Tweetorial 7👨🏽‍🏫 1L tx selection ➡️ impacts 2L💊🧪options! As beautifully illustrated by @JuliaRotow at #TTLC25:	Neutral	3,351
Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD	Results from #FLAURA2 presented at IASLC #WCLC25. 🔹PFS previously presented (primary end point), superior with combination c/w osi alone. 🔹OS presented today, with a mOS 47.5mo Safety as previously reported. Fantastic presentation @dplanch…	Positive	3,347
Shankar Siva @_ShankarSiva	🚨FLAURA2 (n=557; 1L EGFRm advanced NSCLC, incl ~40% CNS mets): shows final OS data for 1st-line osimertinib + chemo ➡️ median OS ~47.5 mo vs 37.6 mo (HR 0.77; p=0.02); ➡️ 4-yr OS 49.1% vs 40.8%. ➡️ Longer exposure to osi + 2nd line chem…	Neutral	3,158
Joshua Reuss @Joshua_Reuss	Dr. @JuliaRotow makes her case for FLAURA2 osimertinib+chemotherapy in EGFRm NSCLC at #WinterLung26. Benefit extends beyond classical "high risk" subgroups.	Neutral	2,830
Roberto Ferrara @RobertoFerrara_	TOP trial shows benefit of osi+chemio in EGFR mut/P53 mut NSCLC with early separation of OS curve (not occurring in Flaura2). P53 mut could be DISRUPTIVE and non-DISRUPTIVE which are functionally different categories. Trials should catch th…	Neutral	2,216
Oriol Mirallas MD @DrMirallas	#ASCO24 Masterclass by @JordiRemon mechanisms of resistance to #EGFR #NSCLC 1. On-target 🎯 2. Bypass 👣 3. Histo transf #SCLC #SCC 4. Unknown 📌 SoC 1L #FLAURA #MARIPOSA #FLAURA2 📌 CT+/-BEV+/-IO? after #TKI PD no clear #OS ⬆️ HARMONi-A? 👉🏼 Se…	Neutral	2,192
Eric K. Singhi, MD @esinghimd	FIRST debate of #TTLC24, @RamalingamMD v @JSabari Chemotherapy plus osimertinib: Should this be our 1L SOC for patients w/ EGFR mutant mNSCLC? Without OS readout, shared decision-making remains PARAMOUNT Very timely given the recent @F…	Neutral	2,117
Andres F. Cardona @AndresFCardonaZ	My perception, after using FLAURA2 combination for months, is that it increases hematological and liver toxicity significantly, at least in the Latin population that I treat. Have you had a similar impression in other latitudes?	Neutral	1,957
Julien Mazieres @JulienMazieres	Highly expected presentation #WCLC2025 Positive OS in FLAURA2 trial with “limited” exposure to chemo. Clear impact on pts outcome but also on pts journey…	Nuanced	1,834
Isabel Preeshagul @ipreeshagul	Share the stage with the INCREDIBLE @CharuAggarwalMD ?! I’m in #nylung24 Take home 🏡 from our session 1) mariposa vs flaura2 vs flaura , pt driven, no right answer 2) SC Ami- less infusion reaction 13 %vs 66% with IV , less chair time 3) …	Neutral	1,722
Alfredo Addeo MD @Alfdoc2	Dr Langen discussing FLAURA2 data. Too early to pick FLAURA2 regimen as new SOC. CtDNA might help us to determine when and if we need to intensify treatment #ELCC24 @myESMO	Neutral	1,713
Dr. Luis E. Raez @LuisRaezMD	FLAURA2 Overall survival presented at #WCLC2025 showing an increase of survival of chemo +osi with 47.5 months HR 0.77 good news for our patients @EGFRResisters @EGFRSummit @EgfrUk @egfr @EGFRmNSCLC @DFEGFRcenter #lungcancer #LCSM	Neutral	1,546
Manuel Dómine, MD, PhD @ManuelDomine	Flaura-2 Second interim Overall Survival analysis witha maturity of 41%. 3 years OS 64% vs 50% HR 0, 70. #ELCC2024 @OncoAlert @myESMO	Neutral	1,524
Dr. Estela Rodriguez @Latinamd	Sometimes the FDA approves treatments that I’m not ready to start in all patients. .. @FDAOncology approves #osimertinib for 1st Line metastatic EGFR NSCLC based on #FLAURA2 which compared chemo+ osi vs osi alone w ⬆️ PFS but ⬆️⬆️toxicity…	Nuanced	1,300
Diego A. Díaz-García @diegoadiazg	🚨 FLAURA2 OS Results: In EGFRm advanced NSCLC, osimertinib + chemotherapy improved OS vs osimertinib alone (47.5 vs 37.6 mo; HR 0.77). Reinforces combinations as preferred first-line options. @IASLC #CánCare #nsclc #egfr #lcsm #wclc25	Positive	1,244
D. Ross Camidge @DRCamidge	I favor it as a means to an end. To get to maximal response before consolidation radiation. If viewed this way chemo doesn’t have to start day 1. Can be after mex response on tki	Neutral	1,180
Daniela Scattolin @DanielaScattol1	How will the EGFRmut NSCLC treatment landscape change? Personalized approach is the FUTURE ✨ #ELCC24 #FLAURA2 #MARIPOSA #MARIPOSA2	Neutral	974
Santhosh Ambika @RenoHemonc	New EGFRm consult used to be straight forward..soon it is will be like - ‘ Look we have 3 options ……..’	Neutral	915
Noemi Reguart @NReguart	Great insights from Tony Mok @TonyMok9 and Solange Peters @peters_solange at the Global Lung Diagnostics Summit — spotlight on #EGFR BM and subgroups of interest in the evolving landscape of #LungCancer	Positive	839
Balazs Halmos @DrSteveMartin	Certainly CNS disease seems key in decision-making as: ☑️poor progn w osi alone ☑️very large PFS benefit w projected QOL impact ☑️anticipated OS benefit given delta in PFS But even there amount of CNS disease prob relevant as per👇data More …	Nuanced	724
Alan Reyes-M.D @dralanreyesonco	Too much toxicity: Chemo/ TKI G3 AE’s 53% vs TKI mono G3 AE 11%, with no OS benefit… should we use only in CNS mets patients?? #FLAURA2 #EGFRm #NSCLC	Nuanced	622
Narjust Florez, MD, FASCO @NarjustFlorezMD	We are here … From FLAURA-2 updates to Northstar - the evolution for the treatment of EGFR lung cancer has accelerated but still we need more for our patients. It doesn’t end here - it starts now #ESMO25	Nuanced	593
Antonious Z. Hazim, MD @AHazimMD	Without an OS benefit, hard to find an argument to use this regimen	Negative	553
Tom Newsom-Davis @tnewsomdavis	I think this has a role, but in the minority of patients in the real-world setting QoL with non-chemo 1L treatment not to be underestimated PRO data shows most preferTKI only regimen	Nuanced	433
Crispin Hiley @crispinhiley	The trial that should be done - hopefully coming sometime in the future somewhere. A great discussion on monotherapy vs combo therapy for patients with EGFR mutation positive NSCLC. Patient relevant endpoints so key. #ELCC25	Positive	430
Bijoy Telivala @BijoyTelivala	Judgement call Older / Frail pt - Osi alone Others can discuss options but if not choosing Osi alone , I would prefer Mariposa rather than Flaura protocol Hoping for the Subq version of Avimantanib	Nuanced	368
David Heredia. @HerediaOncologo	First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes Trend of OS benefit. #ELCC2024 @myESMO	Neutral	368
Adam Dangoor @DrAdamDangoor	Adds to increasingly complex decision making in NSCLC. We need to get much better at using data to stratify patients, & then have decision support applications so that all oncologists can be offering treatment as close to optimal for surviv…	Neutral	338
Martin Dietrich, MD, PhD @DoctorDietrich	FLAURA2 Update: OS trend HR=0.75, not final but improved from HR=0.9 at 1st interim analysis. Median OS in osi arm 36 months, similar to FLAURA results . Postprogression tx with old concern of ?combination > sequential tx. SOC for 1st line …	Negative	276
Clay Reed, MD @ClayReedMD	Frail (or someone very interested in QOL): Osi single agent Someone fit with brain Mets or who wants slightly more agressive care- Osi + chemo Someone young and fit: Amivant + laz	Positive	204
Dipesh Uprety MD FACP @DipeshUpretyMD	FLAURA-2 @NEJM ➡️Pts w/ advanced NSCLC randomized to osimertinib versus chemo plus Osi ➡️↑ OS with chemo plus osi (Md OS: 47.5 mo vs. 37.6 mo; HR: 0.77) @OncoAlert @BTFCancerNews #LCSM	Neutral	147
Evan Thomas MD/PhD @EvanThomas84	Shouldn’t the curves recross or at least start to converge at 39 months?	Neutral	142
Dr. Rajib Bhattacharjee @rajib99	They should have made a preplanned analysis for exon 21 mut. Without clear benefit hard to press for such a toxic regimen. Prescribed it to a patient with L858R and pontine mets. Too much toxicity. Two cycles done and two interim admission…	Negative	123
cadranel jacques @CadranelJ	Strongly suggest that not all patients should received Flaura 2 intensification and that today and unexpectedly molecular alterations except del/858 are less indicative than metastatic burden and sites of metastases. What is the place for t…	Neutral	120
Bertrand Delsuc @BertrandBio	It's my understanding that Astra positions FLAURA2 only for subpopulations like pts with brain mets or other subgroups of interest with a larger clinical benefit than in ITT, given the tox addon of chemo. For the other settings, they're cur…	Neutral	113
Anis Toumeh, MD @AnisToumeh	I like both. 3 year OS seems comparable, but FLUARA2 with median exposure to chemo all together of 8 months. Would SubQ Ami make a difference for you?	Nuanced	111
Mike Pishvaian @MPishvaian	#TumorBoardTuesday That certainly makes sense...so in the real world, probably a low threshold to drop pem if there are significant AEs	Neutral	57
José Sandoval @JLSandoval	PFS without OS or QoL benefit in this case will just mean added Tox. AZ will sell more, patients will pay the price in Tox and society will pay the monetary cost.	Negative	48
Prabhat Gautam Roy, MD @Prabhat_DM_Onco	Great summary of MARIPOSA, FLAURA2, etc.! We just published a narrative review on recent advances in EGFR-mutated advanced NSCLC, covering first-line combos, resistance mechanisms, and post-progression strategies. Check it out: https://t.co…	Neutral	19

See full FLAURA2 conference coverage & trial data →

Trial 3 · NCT02511106

What do oncologists think of the ADAURA trial (TAGRISSO®)?

ADAURA — Adjuvant EGFR-mutated (ex19del / L858R) stage IB–IIIA NSCLC after complete resection

FDA APPROVED · Dec 2020FDA-approved December 18, 2020, for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

Physicians are broadly favorable, with real nuance on ADAURA: 35% of 49 verified physician voices positive, 16% nuanced (praising the result while flagging a caveat), 39% neutral, 10% critical.

35%

16%

39%

10%

Positive 35% Nuanced 16% Neutral 39% Critical 10%

Denominator: 49 distinct verified physician voices across 107 oncologist posts, 2020-05-31 to 2026-05-31. Sponsor: AstraZeneca

See full ADAURA conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT02511106 · FDA — ADAURA adjuvant approval (Dec 2020)

FDA approval (December 18, 2020): osimertinib for adjuvant therapy after tumor resection in EGFR exon 19 deletion / exon 21 L858R NSCLC (based on ADAURA, NCT02511106).

Physician voices — verbatim

#ASCO23 ADAURAble results! How it started How it is going 👇 👇

Balazs Halmos

@DrSteveMartin

Have a look at my comment on the control arm of the ADAURA trial. Of course I am not discussing the relevance of the results, but the importance of an optimal control arm, for ethical and methodological reasons, also in terms of post-progression treatment

Massimo Di Maio

@MassimoDiMaio75

Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023 38.5% of people who had recurrence got OSI (very low!) That just isn't good enough Brain staging is suboptimal= occult met disease Would you let your mother be on the control arm and not get OSI on progression?

Vinay Prasad MD MPH

@VPrasadMDMPH

Full physician voice list (49)

Physician	Comment (verbatim)	Sentiment	Impressions
Vinay Prasad MD MPH @VPrasadMDMPH	Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023 38.5% of people who had recurrence got OSI (very low!) That just isn't good enough Brain staging is suboptimal= occult met disease Would you let your mother be on the control a…	Negative	103,070
Drew Moghanaki 🐕 @DrewMoghanaki	Hey @JackWestMD, did you already see p25 of the #ADAURA supplementary appendix? Curious of your thoughts given 88% of pts in the placebo arm who developed progression and were fit enough to get more tx got a TKI. #ASCO23 https://t.co/vRV8Fe…	Neutral	88,661
Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD	Before we all continue to pile on #ADAURA, can someone tell me % of patients who received Immunotherapy upon progression on IM-010 or KN-91. See figure. I will remind you that immunotherapy alone or in combination is THE SOC for 1L Metas…	Neutral	80,524
Nathan A. Pennell MD, PhD, FASCO @n8pennell	Please check out this cost effectiveness analysis done by @LemmonOnc and I based on various projected final ADAURA OS results. We calculated that adjuvant osimertinib would be cost effective if the OS benefit was 0.7 HR or lower, so 0.49 ex…	Neutral	42,496
Bishal Gyawali @oncology_bg	So only 79 of 343 patients (23%) in placebo arm got subsequent osimertinib in #ADAURA. Would love to see OS results subgrouped by those who got subsequent osi versus those who did not. #ASCO23	Negative	41,217
Jeff Ryckman @jryckman3	"I have to start with #ADAURA because the Cheerleaders are out there in full force." Bring the truth, VP! Oncology has too many Cheerleaders. Put down the pom-poms and think about trial design, folks. Let's put patients front and cent…	Neutral	39,257
Dr Riyaz Shah @DrRiyazShah	ADAURA; look at NEJM supplementary ; 7% 5y landmark advantage for those who got adjuvant chemo. My view will be to recommend adjuvant chemo before adjuvant osimertinib #ASCO23 #LCSM	Negative	32,082
H. Jack West, MD @JackWestMD	My colleague @n8pennell & I have been askeyd to write a commentary piece together about ADAURA. In the spirit of working together, we have agreed to do so. What do you see as the most likely outcome?	Neutral	21,614
Balazs Halmos @DrSteveMartin	#ASCO23 ADAURAble results! How it started How it is going 👇 👇	Positive	21,191
gilberto lopes @GlopesMd	If anyone had doubts: @asco #asco23 impressive results from ADAURA - OS hazard ratio [HR] of 0.49; 95.03% confidence interval [CI] 0.33-0.73; p=0.0004), and in the overall trial population (Stages IB-IIIA) (18% data maturity, OS HR of 0.49;…	Positive	18,875
Charles Swanton @CharlesSwanton	ADAURA trial of adjuvant osimertinib in egfrm early stage NSCLC shows 12% overall survival benefit consistent across all subgroups and independent of prior adjuvant chemotherapy use - fabulous news for patients with egfrm early stage lung c…	Positive	16,789
Roy Herbst @DrRoyHerbstYale	I am excited about the plenary session starting in a few minutes ⁦@YaleCancer⁩ ⁦@ASCO⁩. I will be presenting the overall survival data from the ADAURA study ⁦for early stage EGFR mutant lung cancer. more soon…⁦@ASCOPres⁩	Positive	13,053
Massimo Di Maio @MassimoDiMaio75	Have a look at my comment on the control arm of the ADAURA trial. Of course I am not discussing the relevance of the results, but the importance of an optimal control arm, for ethical and methodological reasons, also in terms of post-progre…	Nuanced	12,969
Stephen V Liu, MD @StephenVLiu	#ASCO24 Dr. @TommyJohn00 shows #MRD analysis from ADAURA (adjuvant osimertinib for #EGFR NSCLC). This is a tumor-informed MRD assay (individual for each patient).	Neutral	8,178
Ziad Bakouny, MD, MSc @ZiadBakouny	Now @DrRoyHerbstYale with the third presentation of the plenary session with the #ADAURA study. Now with an overall survival benefit with osimertinib in patients with EGFR+ NSCLC. @ASCO #ASCO23 @YaleCancer @YaleMed @IMG_Oncologists @Onco…	Neutral	6,554
Julien Mazieres @JulienMazieres	Looking at ADAURA & LAURA control arms we can wonder whether localized EGFR lung cancer really exists. Multifocal lung extension & mets likely occur very early underlining the need for targeted tt regardless of tumor stage. ctDNA might help…	Neutral	6,554
Jonathan Spicer MD PhD @DoctorJSpicer	#ALINA, #ADAURA and #KN671 were all smiles today @myESMO #ESMO23! Love these guys!	Positive	4,913
Ben Solomon @bensolomon1	Outstanding presentation from @TommyJohn00 about the utility of tumour informed MRD analysis of ctDNA in the ADAURA trial. Glimpsing at the future of disease monitoring in lung cancer. @_ShankarSiva @drshieldsmd #ASCO24	Positive	4,847
Dr Rishabh Jain @DrRishabhOnco	#ASCO26 🚨 RET-positive early-stage NSCLC just got its ADAURA moment. Phase 3 LIBRETTO-432 showed adjuvant selpercatinib dramatically improved EFS after definitive therapy in stage IB-IIIA RET fusion+ NSCLC. 🧪 Phase 3, double-blind 👥 N=151…	Positive	4,716
Lei Deng, MD (He/Him) @LeiDeng3	The 3 #LCSM studies that I am waiting for at #ASCO23 - KEYNOTE 671, ADAURA & LUNAR. See the Context, Design, and What to Look For.	Neutral	4,221
Patrick Forde @FordePatrick	It was a pleasure to reviewing this excellent MRD work from the ADAURA trial led by Drs. ⁦⁦⁦@DrRoyHerbstYale⁩ ⁦@ThomasW35874311⁩ & co. Key addition to the knowledge in resected lung cancer, primetime for MRD is getting close! #lcsm	Positive	3,720
Eddie Cliff @Eddie_Cliff	Thanks @MassimoDiMaio75 for raising the lack of crossover in ADAURA @NEJM I enjoyed the discussion w @JackWestMD & @n8pennell on @chadinabhan's podcast: https://t.co/8fsu3ON1of We also discuss the ethics of crossover in our recent @JCO_A…	Positive	3,147
Jarushka Naidoo @DrJNaidoo	#ASCO24 Lung orals🔥 MRD analysis of Ph III ADAURA trial: - using tumor-informed approach, 91% samples assessable for MRD - MRD events: 13% osi v 49% pbo - MRD/‘molecular recurrence’ occurred 4.7m before radiologic @TommyJohn00⁩ ⁦@ASCO⁩ ⁦@…	Positive	2,790
Mark Lewis, MD, FASCO @marklewismd	In a superb & balanced discussion @LeciaSequist highlights the potential CNS-protective benefits of indefinite EGFR TKI (citing ADAURA)	Positive	2,525
Bertrand Delsuc @BertrandBio	$AZN TAGRISSO achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial #ASCO23 OS HR 0.49 https://t.co/Z0C0gcVcpd	Positive	2,345
Rafeh Naqash, MD @thenasheffect	Bingo ! OS met in #ADAURA presented by ⁦@DrRoyHerbstYale⁩ at ⁦@ASCO⁩ #ASCO23 . The ONE session I was able to attend !😄	Positive	2,083
Bartomeu Massuti @bmassutis	Results of monitoring ctDNA. In ADAURA trial seems to correlate MRD with recurrence and outcomes. #ASCO24 @OncoAlert	Neutral	2,070
Fabrice Barlesi @barlesi	Smart discussion of ADAURA by @bensolomon1 #ASCO23	Neutral	1,331
Chul Kim @chulkimMD	#ADAURA OS data by Dr. Herbst. In stage II–IIIA, OS HR 0.49; 5-yr OS 85% with #osimertinib vs 73% with placebo. In stage IB–IIIA, OS HR 0.49 favoring osi. Benefits seen across stages IB/II/IIIA (HR for OS: 0.44/0.63/0.37)! #ASCO23	Neutral	1,159
Dr. Nina Niu Sanford @NiuSanford	So how do y’all really feel about ADAURA?	Neutral	1,112
Christine Lovly, MD, PhD @christine_lovly	Agree! I am very enthusiastic about the ADAURA data. But can we truly say “cure” with the available data? @JackWestMD	Nuanced	896
Dr Amol Akhade @SuyogCancer	Key is the data of those 79 which got Osimertinib on progression. I am sure this will eventually come out . And that will probably throw enough light on correct magnitude of benifit of adjuvant Osimertinib, if any .	Neutral	836
Dr. Estela Rodriguez @Latinamd	As a fellow cat owner, I’m supporting @n8pennell’s perspective but I’m sure you will find common ground that benefits all patients.	Nuanced	807
Manuel Dómine, MD, PhD @ManuelDomine	ADAURA: Molecular residual disease (MRD) analysis. MRD events were detected + frequently in placebo vs osi. MRD identified recurrence with a median lead time of 4.7 m. Pts receiving osi were more likely to be DFS and MRD event-free vs place…	Neutral	794
Pramesh CS @cspramesh	Clearly not a proper cost effectiveness analysis when just one third of patients got the standard of care? And cost effectiveness is relative? And the US spending 19% GDP on Healthcare with vastly inferior outcomes cannot dictate what is "c…	Negative	646
Fred R. Hirsch @fred_hirsch	Great discussion in ASCO plenary session by our previous “fellow”, Dr. Ben Solomon discussing adjuvant EGFR therapy in NSCLC ! Congrats to Dr.Herbst as presenter and Dr. Solomon as discussant!	Positive	494
Robert S Miller, MD, FACP, FASCO, FAMIA-he/him @rsm2800	ADAURA OS results from Sunday now incorporated into updated @ASCO guideline for the management of Stage III NSCLC https://t.co/yOqVK21a43 #ASCO23	Neutral	397
Allison Chang @aebchang	Yes very sobering, and reminiscent of the sharp decrement in PFS after pts discontinued osi in ADAURA. We don’t think the answer is to keep everyone on indefinite therapy (a la LAURA), but we need to figure out: 1) how to cure more peopl…	Nuanced	386
Eric K. Singhi, MD @lungoncdoc	I’m here for BOTH viewpoints!! Looking forward to this @JackWestMD @n8pennell!! #lcsm @LungCancerRx	Positive	350
Catherine A. Shu, MD @CatherineShuMD	Yes!!! I see all this all the time in my practice. That being said, it was chilling to see the results of #ADAURA being presented by Roy Herbst!	Positive	322
Giuseppe Procopio @g_procopio_	i am fully agree with you Max.This is a common problem	Negative	275
Vladmir C. Cordeiro de Lima, MD, PhD @ClaudioVladmir	👍When you're about to present a potentially paradigm-shifting study, you better make all effort to leave no room for questioning. In this particular case: no PET / brain RM before osi initiation, adjv chemo at invest discretion, OS as 2nd e…	Nuanced	249
Giuseppe Banna @gbanna74	Although... 1. OS not significant in stage IB & II as well as ex21 L858R 2. about 3 fold patients than placebo discontinued due to their decision or toxicity 3. only 43% progressed to placebo received Osi among those receiving Egfr tki	Nuanced	218
Peter B. Bach, MD @peterbachmd	And haven’t edited out the susceptibility to the mutation yet because, well, prevention never a priority	Neutral	208
Dr. Bosch-Barrera @BoschBarrera	You cannot give osimertinib adjuvant if a patient received adjuvant chemoradiotherapy (ie for R1) because for safety reasons were excluded from Adaura, but you have a phase III after radical chemoradiation Laura... I have missed something?	Nuanced	205
Nagashree Seetharamu @NagashreeSeeth1	A follow up study looking at practical utility and impact on HRQoL with monitoring eagerly awaited	Neutral	131
Vidya Kollu MD @KolluVidya	#ASCO23 #Plenary session #Lungcancer #adjuvant osimertinib # stage II-IIIA ADAURA study -updated results it only gets better! @Roy Herbst et al. https://t.co/yCdd4aoSj1	Positive	73
Alex Menter @Alexmenter	I agree. But we also had a huge argument about ADAURA RFS without OS in 2020. I agree this is different because of the established track record of cure with these drugs. There is still a lot that is unknown about whether TKIs ever cure NSCL…	Nuanced	57
Patrick C. Ma, MD @PatrickCMa1	Much anticipated Plenary presnetation of ADAURA study by Dr. Roy Herbst. Just started.	Neutral	0

See full ADAURA conference coverage & trial data →

Trial 4 · NCT03521154

What do oncologists think of the LAURA trial (TAGRISSO®)?

LAURA — Unresectable stage III EGFR-mutated (ex19del / L858R) NSCLC after chemoradiotherapy

FDA APPROVED · Sep 2024FDA-approved September 25, 2024, for locally advanced, unresectable (stage III) NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations and whose disease has not progressed during or after platinum-based chemoradiation therapy.

Physicians are broadly favorable, with real nuance on LAURA: 29% of 86 verified physician voices positive, 16% nuanced (praising the result while flagging a caveat), 42% neutral, 13% critical.

29%

16%

42%

13%

Positive 29% Nuanced 16% Neutral 42% Critical 13%

Denominator: 86 distinct verified physician voices across 224 oncologist posts, 2024-02-19 to 2026-04-01. Sponsor: AstraZeneca

See full LAURA conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT03521154 · FDA — LAURA stage III approval (Sep 2024)

FDA approval (September 25, 2024): osimertinib for unresectable stage III EGFR exon 19 deletion / exon 21 L858R NSCLC without progression after platinum-based chemoradiation (based on LAURA, NCT03521154).

Physician voices — verbatim

LAURA passes the "truck test" to a rousing ovation at #ASCO24 plenary session, with osimertinib given to patients with locally advanced unresectable stage III EGFRmut NSCLC with no progression following definitive chemoRT #lcsm https://t.co/K8Iwlc9Rbv

Mark Lewis, MD, FASCO

@marklewismd

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist

Noemi Reguart

@NReguart